We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
HiFiBiO Therapeutics has raised $75m in a Series D funding round, led by Mirae Asset Financial Group, to expedite its pipeline with two immuno-oncology programmes.